Company Profile
Design Therapeutics Stock Price, News & Catalysts
- Ticker:
- DSGN
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
14.99 USD (-3.66%)
Close
Last updated: August 21, 2026
635M USD
Market cap
Why the stock is moving
As of Aug 21, 2026, DSGN closed down 3.66% at $14.99. No new same-company headline was identified in the current news window.
Company overview
GeneTAC Platform
Design Therapeutics develops GeneTAC small molecules that bind genomic repeat sequences and modulate transcription. The platform is designed either to increase expression of a deficient gene or reduce expression of a toxic mutant gene.
DT-216P2
DT-216P2 is being developed for Friedreich ataxia and is designed to increase endogenous frataxin expression. The Phase 1/2 RESTORE-FA trial measures safety, pharmacokinetics and changes in frataxin RNA and protein in blood and muscle.
DT-168
DT-168 is in a Phase 2 biomarker trial for Fuchs endothelial corneal dystrophy. The study evaluates corneal-endothelium biomarkers in patients already scheduled for transplant surgery.
DT-818
DT-818 is designed to selectively reduce transcription of the mutant DMPK allele in myotonic dystrophy type 1. A Phase 1 multiple-ascending-dose trial will assess safety and correction of disease-associated RNA mis-splicing.
Earlier Genetic-Disease Pipeline
Design is also characterizing GeneTAC candidates for Huntington’s disease and conducting discovery work across additional genomic disorders.
Future catalysts
- Initial dosing in the Phase 1 DT-818 trial planned in the first half of 2026, with results expected in 2027.
- DT-216P2 frataxin biomarker update expected in the second half of 2026.
- Phase 2 biomarker data for DT-168 expected in the second half of 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Design Therapeutics (DSGN)?
Design Therapeutics (DSGN) most recently closed at 14.99 USD, a -3.66% move versus the previous session.
What is the market cap of Design Therapeutics (DSGN)?
Design Therapeutics currently has a market capitalization of 635M USD on BioPharmSignal.
What does Design Therapeutics do?
GeneTAC Platform Design Therapeutics develops GeneTAC small molecules that bind genomic repeat sequences and modulate transcription. The platform is designed either to increase expression of a deficient gene or reduce expression of a toxic mutant gene. DT-216P2 DT-216P2 is being developed for Friedreich ataxia and is designed to increase endogenous frataxin...
On which exchange is DSGN stock listed?
Design Therapeutics (DSGN) is associated with NASDAQ, United States, Biopharma.
What is DT-216P2?
DT-216P2 frataxin biomarker update expected in the second half of 2026.
Which conditions is Design Therapeutics targeting with DT-216P2?
Design Therapeutics is associated with genetic disease based on its company overview and current catalyst commentary.
How does Design Therapeutics describe recent progress with DT-216P2?
DT-216P2 frataxin biomarker update expected in the second half of 2026.
What is RESTORE-FA?
The Phase 1/2 RESTORE-FA trial measures safety, pharmacokinetics and changes in frataxin RNA and protein in blood and muscle.